Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Vivoryon Therapeutics NV's annualizedNet Income for the quarter that ended in Dec. 2025 was €-6.76 Mil.
Vivoryon Therapeutics NV's average Total Assets over the quarter that ended in Dec. 2025 was €6.97 Mil. Therefore, Vivoryon Therapeutics NV's annualized ROA % for the quarter that ended in Dec. 2025 was -97.01%.
The historical rank and industry rank for Vivoryon Therapeutics NV's ROA % or its related term are showing as below:
XAMS:VVY'
s ROA % Range Over the Past 10 Years
Min: -105.31 Med: -76.97 Max: -31.35
Current: -105.31
During the past 13 years, Vivoryon Therapeutics NV's highest ROA % was -31.35%. The lowest was -105.31%. And the median was -76.97%.
XAMS:VVY's ROA % is ranked worse than 84.04% of 1416
companies
in the Biotechnology industry
Industry Median: -32.985
vs XAMS:VVY: -105.31
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vivoryon Therapeutics NV's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's ROA % distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
Vivoryon Therapeutics NV (XAMS:VVY) has a ROA % of -97.01% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vivoryon Therapeutics NV and its competitors. According to the industry distribution chart, Vivoryon Therapeutics NV ranks #1190 out of 1416 companies in the Biotechnology industry, placing it in the top 84%.
Is Vivoryon Therapeutics NV's ROA % too high?
Vivoryon Therapeutics NV's current ROA % is -97.01%. Based on the distribution chart, Vivoryon Therapeutics NV ranks #1190 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vivoryon Therapeutics NV has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vivoryon Therapeutics NV ranks #1190 out of 1416 companies for ROA %. This places Vivoryon Therapeutics NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current ROA % is -97.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (XAMS:VVY) has a current ROA % of -97.01%. The current ROA % is -97.01%. Vivoryon Therapeutics NV's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Vivoryon Therapeutics NV (XAMS:VVY), the current ROA % is -97.01% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
25GF Score
Get the complete analysis for XAMS:VVY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAMS:VVY has been successfully added to your 
